WI-ROCKWELL-AUTOMATION
14.3.2023 12:01:40 CET | Business Wire | Press release
Rockwell Automation, Inc. (NYSE: ROK), the world’s largest company dedicated to industrial automation and digital transformation, today announced the results of the 8th annual “State of Smart Manufacturing Report.” The global study surveyed more than 1,350 manufacturers across 13 of the leading manufacturing countries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230314005374/en/
Rockwell Automation announced the results of the 8th annual “State of Smart Manufacturing Report” (Photo: Business Wire)
This year’s report reveals a focus on delivering profitable growth without sacrificing quality, an emphasis on accessing data’s true potential, and increasing adoption of technology to build resilience, enable agility, increase sustainability, and address workforce challenges.
Key global findings include:
- Twice as many manufacturers believe their organization lacks the technology needed to outpace the competition, as compared to 2022.
- 4 out of 5 manufacturers still lack an end-to-end supply chain planning solution.
- Cybersecurity risks rank highest as the obstacle respondents are looking to mitigate with smart manufacturing initiatives.
- 45% of manufacturers cite “improving quality” as the main positive outcome they want to achieve with smart manufacturing initiatives.
- 89% of manufacturers plan to maintain or grow employment due to technology adoption. Additionally, 36% of respondents believe they will be able to repurpose existing workers due to their increasing use of technology.
- Of the 95% of manufacturers who have formal or informal ESG policies in place, 42% cite “improving efficiencies” as the top driving factor for pursuing ESG initiatives.
“Manufacturers are continuing to seek opportunities for profitable growth but are realizing that uncertainty in workforce availability is impacting quality, along with their ability to meet evolving customer needs,” said Veena Lakkundi, senior vice president, Corporate Strategy and Development, Rockwell Automation. “The survey found that smart manufacturing technology is enabling manufacturers of all sizes to optimize more resilient, agile, and sustainable solutions that accelerate transformation. If we’ve learned anything from history, it’s that organizations that invest in innovation, with a bias for action, during times of uncertainty can outpace competitors.”
Based on the survey findings, technology is crucial to mitigating risk and delivering growth. However, for one-third of manufacturers, the range of available systems and platforms is leading to “technology paralysis” – an inability to decide between solutions. Manufacturers can overcome this indecision by choosing a partner with relevant industry expertise and experience who can advise and guide them in implementing a fit-for-purpose solution to achieve desired outcomes.
“At Rockwell, we combine the power of our portfolio of industry solutions with our second-to-none partner ecosystem to serve as a trusted advisor to leading companies around the world,” said Lakkundi. “As the biggest company focused solely on industrial automation and digital transformation, we work to make the complex simple and meet companies where they are in their journeys.”
The full findings of the report can be found here.
Methodology
This report analyzed feedback from 1,353 respondents from 13 of the top manufacturing countries with roles from management up to the C-suite and was conducted in association with Sapio Research and Plex Systems. The survey covered discrete, process, and hybrid industries across a balanced distribution of company sizes with revenues spanning $10 million to over $10 billion, providing a wide breadth of manufacturing business perspectives.
About Rockwell Automation
Rockwell Automation, Inc. (NYSE: ROK) is a global leader in industrial automation and digital transformation. We connect the imaginations of people with the potential of technology to expand what is humanly possible, making the world more productive and more sustainable. Headquartered in Milwaukee, Wisconsin, Rockwell Automation employs approximately 26,000 problem solvers dedicated to our customers in more than 100 countries. To learn more about how we are bringing the Connected Enterprise to life across industrial enterprises, visit www.rockwellautomation.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005374/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datavault AI Announces Board of Directors Has Requested Management’s Complete Plan for Dividend Spin-Out of Acoustic Sciences Division into Stand-Alone Public Company7.5.2026 15:07:00 CEST | Press release
Initial planning calls for Data Sciences Division to focus efforts in cyber secure infrastructure with dedication in fintech and patented Information Data Exchange® (IDE®) Management will harness its API Media acquisition, robust patent portfolio, ADIO® Inaudible Tones, WiSA® and Dolby® partnerships to establish worldwide acoustic industry standards in high-definition wireless transmission, spatial-audio control and interoperability Plan includes API media’s stand-alone and renewed execution of WiSA semiconductor and software modules strategy with an R&D effort targeted to new robotic and drone applications Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a pioneering technology licensing company seeking to redefine data valuation, monetization, and secure Web 3.0 experiences, today announced that Company management has commenced its evaluation of a potential dividend spin-out of the Company’s Acoustic Sciences division which includes its ADIO®, WiSA®, Event Citadel™,
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 14:50:00 CEST | Press release
First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs)at the 2026 EADV SymposiumThe vast majority of patients achieving EASI50 at Week 8 and continuing double-blind, as needed treatment with Opzelura® (ruxolitinib) cream through Week 24 demonstrated disease control, with 84.3% achieving EASI75 (a ≥75% improvement in the Eczema Area and Severity Index score from baseline) and 70.6% achieving IGA-TS (Investigator’s Global Assessment Treatment Success)Data support Type-II variation application submitted for ruxolitinib cream 1.5% for the treatment of adults with moderate AD in the European Union (EU), feedback expected in 1H 2026 Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with mode
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release
Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release
“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
